PBR-06
Multiple System Atrophy, Parkinsonian Type
Explore 2 assets in Multiple System Atrophy, Parkinsonian Type →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Brigham and Women's Hospital
Modality
Small molecule
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04616456CT.gov Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple System Atrophy, Parkinsonian Type
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| PBR-06 (this asset) | Brigham and Women's Hospital | Early P1 | CC · 43 |
| Carbidopa | Julien Bally | P1/2 | CCC |
| Levodopa | Julien Bally | P1/2 | CCC |
| Verdiperstat | Brigham and Women's Hospital | Early P1 | CC |
| Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells | Indonesia University | N/A | D |
Other indications for PBR-06
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P3 | CCC · 55 |
| Stroke Disorder | — | P2 | CC · 47 |
| Multiple Sclerosis | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. PBR-06 in Multiple System Atrophy, Parkinsonian Type. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pbr-06-multiple-system-atrophy-parkinsonian-type
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →